References

This is the reference list to the ACE Clinical Guideline “Venous thromboembolism - Treating with the appropriate anticoagulant and duration”.

1. Lutsey PL, Zakai NA. Epidemiology and prevention of venous thromboembolism. Nat Rev Cardiol. 2023;20(4):248-62.
2. RIETE Registry. Death within 30 days: RIETE Registry; 2024. Available from: https://rieteregistry.com/graphics-interactives/dead-30-days/.
3. Lee LH, Gallus A, Jindal R, et al. Incidence of Venous Thromboembolism in Asian Populations: A Systematic Review. Thromb Haemost. 2017;117(12):2243-60.
4. Lip GY, Hull RD. Venous thromboembolism: Initiation of anticoagulation. 2023. Accessed 11 Aug 2023. Available from: https://www.uptodate.com/contents/venous-thromboembolism-initiation-of-anticoagulation#H8155842.
5. Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest. 2021;160(6):e545-e608.
6. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543-603.
7. National Institute for Health and Care Excellence (NICE). Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. London: National Institute for Health and Care Excellence (UK); 2023.
8. Kakkos SK, Gohel M, Baekgaard N, et al. European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. Eur J Vasc Endovasc Surg. 2021;61(1):9-82.
9. Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693-738.
10. Kearon C, Ageno W, Cannegieter SC, et al. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost. 2016;14(7):1480-3.
11. Zhuang Y, Dai LF, Chen MQ. Efficacy and safety of non-vitamin K antagonist oral anticoagulants for venous thromboembolism: a meta-analysis. JRSM Open. 2021;12(6):20542704211010686.
12. Chin-Hon J, Davenport L, Huang J, et al. Safety and efficacy of oral anticoagulants in extreme weights. Thromb Res. 2023;231:1-6.
13. Martin KA, Lancki N, Kreuziger LB, et al. DOAC compared with warfarin for VTE in low weight patients: A retrospective cohort study conducted through the VENUS network. Thromb Res. 2023;229:146-8.
14. Zhang H, Xie H, Wang X, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulant in the treatment of patients with morbid obesity or high body weight with venous thromboembolism: A meta-analysis. Medicine (Baltimore). 2023;102(36).
15. Chen A, Stecker E, A Warden B. Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges. J Am Heart Assoc. 2020;9(13):e017559.
16. Key NS, Khorana AA, Kuderer NM, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J of Clin Oncol. 2023;41(16):3063-71.
17. Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927-74.
18. Farge D, Frere C, Connors JM, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022;23(7):e334-e47.

19. Falanga A, Ay C, Di Nisio M, et al. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol. 2023;34(5):452-67.

20. Watson HG, Keeling DM, Laffan M, et al. Guideline on aspects of cancer-related venous thrombosis. Br J Haematol. 2015;170(5):640-8.

21. Royal College of Obstetricians and Gynaecologists. Thrombosis and Embolism during Pregnancy and the Puerperium: Acute Management (Green-top Guideline No. 37b). Royal College of Obstetricians and Gynaecologists. 2015;37b:1-32.

22. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 196: Thromboembolism in Pregnancy. Obstet Gynecol. 2018;132(1):e1-e17.

23. College of Obstetricians and Gynaecologists Singapore, and Chapter of Haematologists, College of Physicians Singapore. Consensus Statement: Venous Thromboembolism in Pregnancy - Recommendations for Prevention, Treatment and Investigation. Academy of Medicine, Singapore. 2021.

24. Kamel H, Navi BB, Sriram N, et al. Risk of a Thrombotic Event after the 6-Week Postpartum Period. N Engl J Med. 2014;370(14):1307-15.

25. Almajdi A, Almutairi S, Alharbi M. Safety and efficacy of apixaban versus low-molecular weight heparin or vitamin-K antagonists for venous thromboembolism treatment in patients with severe renal failure: A systematic review and meta-analysis. Thromb Res. 2023;229:77-85.

26. Bauersachs RM, Lensing AWA, Prins MH, et al. Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment. Thromb J. 2014;12(1):25

27. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e419S-e496S.

28. Lim W, Dentali F, Eikelboom JW, et al. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 2006;144(9):673-84.

29. Wang D, Fan G, Lei J, et al. LMWHs dosage and outcomes in acute pulmonary embolism with renal insufficiency, an analysis from a large real-world study. Thromb J. 2022;20(1):26.

30. Streiff MB, Agnelli G, Connors JM, et al. Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis. 2016;41:32–67.

31. Goto S, Haas S, Ageno W, et al. Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease. JAMA Netw Open. 2020;3(10):e2022886-e.

32. Kujovich JL. Coagulopathy in liver disease: a balancing act. Hematology Am Soc Hematol Educ Program. 2015;2015(1):243-9.

33. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. J Hepatol. 2022;76(5):1151-84.

34. Kearon C, Akl EA. Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. Blood. 2014;123(12):1794-801.

35. Iorio A, Kearon C, Filippucci E, et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med. 2010;170(19):1710-6.

36. Barnes GD, Kanthi Y, Froehlich JB. Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation. Vasc Med. 2015; 20(2):143-52.

37. Khan F, Rahman A, Carrier M, et al. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ. 2019;366:l4363.

38. Kearon C, Kahn SR. Long-term treatment of venous thromboembolism. Blood. 2020;135(5):317-25.

39. Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. EP Europace. 2021;23(10):1612-76.

40. Lee LH, Nagarajan C, Tan CW, et al. Epidemiology of Cancer-Associated Thrombosis in Asia: A Systematic Review. Front Cardiovasc Med. 2021;8:669288.

41. van Hylckama Vlieg MAM, Nasserinejad K, Visser C, et al. The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic review and meta-analysis. eClinicalMedicine. 2023;64:102194.

42. Kirkilesis GI, Kakkos SK, Tsolakis IA. Editor's Choice – A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer. Eur J Vasc Endovasc Surg. 2019;57(5):685-701.

43. Yau CE, Low CE, Ong NY, et al. Non-Vitamin K Antagonist Oral Anticoagulants versus Low Molecular Weight Heparin for Cancer-Related Venous Thromboembolic Events: Individual Patient Data Meta-Analysis. Cancers. 2023;15(24):5887.

44. Samaranayake CB, Anderson J, McCabe C, et al. Direct oral anticoagulants for cancer-associated venous thromboembolisms: a systematic review and network meta-analysis. Intern Med J. 2022;52(2):272-281.

45. Desai R, Koipallil GK, Thomas N, et al. Efficacy and safety of direct oral anticoagulants for secondary prevention of cancer associated thrombosis: a meta-analysis of randomized controlled trials. Sci Rep. 2020;10(1):18945.

46. Imura M, Katada J, Shiga T. Epidemiological Study Regarding the Incidence of Venous Thromboembolism in Patients After Cancer Remission. Cardiol Ther. 2022;11(4):611-23.

47. Kaatz S, Ahmad D, Spyropoulos AC, et al. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13(11):2119-26.

48. Burnett AE, Mahan CE, Vazquez SR, et al. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis. 2016;41(1):206-32.

49. Ng HJ, Chee YL, Ponnudurai K, et al. Consensus recommendations for preventing and managing bleeding complications associated with novel oral anticoagulants in singapore. Ann Acad Med Singap. 2013;42(11):593-602.

50. Tran H, Joseph J, Young L, et al. New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis. Intern Med J. 2014;44(6):525-36.